Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Magazine

Table: Lots of Headaches


AMBIEN HAND-OFF

Under the terms of its licensing deal, Pharmacia (PHA) must return the $902 million-selling sleep aid Ambien to its developer, Sanofi-Synth?labo, this spring. That leaves a big sales hole.

CELEBREX SLOWDOWN

Growth for the company's flagship $3.1 billion arthritis drug Celebrex slowed in 2001 after questions were raised about possible cardiovascular side effects.

FDA WOES

Last year, the Food & Drug Administration delayed approval of injectable painkiller parecoxib and glaucoma treatment Xalcom pending more data.

AGRICULTURAL DRAG

Monsanto's (MON) agribusiness unit has been hurt by resistance to genetically modified seeds. Pharmacia will spin off its remaining stake in the business this fall.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus